On October 12, 2024, Imunopharm Technology Co., Ltd. (referred to as "Imunopharm") announced that the new generation anti-tumor drug IM96 Chimeric Antigen Receptor T-cell Injection (IM96 CAR-T Cell Injection, referred to as "IM96"), developed in collaboration with Peking University Cancer Hospital, has received a clinical trial approval notice from the National Medical Products Administration (NMPA). This is the sixth CAR-T cell drug clinical approval for Imunopharm and the third for treating solid tumors.